Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number			10659093		
Filing Date			2003-09-09		
First Named Inventor John			J. Gilliland et al.		
Art Unit Examiner Name Mattle			3713		
		Matth	hew D. Hoel		
Attorney Docket Number		er	112300-1682 04/20/06		

					U.S.	PATENTS			Remove	
		Kind Code <sup>1</sup> Issue Date		Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1									
If you wis	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	l lease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	n Name of Patentee or Applican of cited Document		Releva	Columns,Lines where ant Passages or Release Appear	
	1	20050277469		2005-1	2-15	Pryzby et al.				
	2	20050282631		2005-12-22		Bonney et al.				
If you wis	h to a	ı dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add	
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>			Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T6
	1	WO 2005113089				2005-12-01	WMS Gaming, Inc			
	2	WO 2005113091				2005-12-01	WMS Garring, Inc			

#### 

2005-12-01

WMS Gaming, Inc.

Date Considered

	4	WO 2005120127			2005-12-15	WMS Gaming, Inc.		
	5	WO 2005117647			2005-12-15	WMS Gaming, Inc.		
If you wis	h to a	dd additional Foreign Pa	atent Document	citation	information pl	ease click the Add butto	n Add	
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country where published.						Ţ5	
	1							
If you wish to add additional non-patent literature document citation information please click the Add button Add								

1 See Kind Cooker of USPTO Patient Documents at year <u>USPTO\_ROD</u> or WIFEP 901.64. <sup>2</sup> Eatine office that instead the document, by the how-litter code (WIFD Standard ST3.) <sup>3</sup> For Junpance patient concurrent, by a conclusion to be year of the Empore transper potent per an unarbor of the patient concern, <sup>4</sup> Kind of document by the appropriate symbols as adicated on the document under WIFO Standard ST.16 if possible. <sup>3</sup> Applicant is to place a check mark here if English Imaguage Internations in attacket.

FYAMINER SIGNATURE

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3

Examiner Signature

WO 2005114598

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10659093		
Filing Date		2003-09-09		
First Named Inventor	John	J. Gilliland et al.		
Art Unit		3713		
Examiner Name	Matthew D. Hoel			
Attorney Docket Number		112300-1682 04/20/06		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
П	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information disclosure statement. See 37 CFR 1 97(e)(1)

### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

٦.	See attached certification statement	

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Renato L. Smith/	Date (YYYY-MM-DD)	2006-04-20					
Name/Print	Renato L. Smith	Registration Number	45117					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.